SCHEMBL22807484

SCHEMBL22807484

C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)nc2ccsc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 12/20 0.70
MAP3K7 O43318 12/20 0.70
FGFR1 P11362 10/20 0.70
MAP2K1 Q02750 5/20 0.70
MAPK1 P28482 3/20 0.70
EGFR P00533 2/20 0.64
ABCB11 O95342 1/20 0.64
ESR1 P03372 1/20 0.64
CHRM2 P08172 1/20 0.64
HTR1A P08908 1/20 0.64
ADRA2A P08913 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
CHRM1 P11229 1/20 0.64
DRD1 P21728 1/20 0.64
TBXA2R P21731 1/20 0.64
SLC6A2 P23975 1/20 0.64
PDE4A P27815 1/20 0.64
ADRA1A P35348 1/20 0.64
OPRM1 P35372 1/20 0.64
DRD3 P35462 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22807499 0.90 EGFR (0.61) SRCMAP3K7FGFR1MAP2K1MAPK1
SCHEMBL22807431 0.87 SRC (0.69) SRCMAP3K7FGFR1MAP2K1MAPK1
SCHEMBL9995397 0.87 EGFR (0.75) SRCEGFRABCB11ESR1CHRM2
SCHEMBL14912693 0.86 EGFR (0.65) SRCMAP3K7FGFR1MAP2K1MAPK1
SCHEMBL22807426 0.84 SRC (0.68) SRCMAP3K7FGFR1MAP2K1MAPK1
SCHEMBL19867214 0.83 PTK2 (0.59) EGFRABCB11ESR1CHRM2HTR1A
SCHEMBL29549166 0.82 MAP3K7 (0.76) SRCMAP3K7FGFR1MAP2K1MAPK1
SCHEMBL22807435 0.82 MAP3K7 (0.76) SRCMAP3K7FGFR1MAP2K1MAPK1
SCHEMBL22807398 0.82 IRAK4 (0.60) SRCMAP3K7FGFR1MAP2K1MAPK1
SCHEMBL22807490 0.82 SRC (0.83) SRCMAP3K7FGFR1MAP2K1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365664-B2 Small molecule inhibitors of SRC tyrosine kinase DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-07-22 US disclosed
US-20220267294-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2022-08-25 US disclosed
EP-3986411-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE Dana-Farber Cancer Institute, Inc. (US) 2022-04-27 EP disclosed
WO-2020257385-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-12-24 WO disclosed
WO-2020257385-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365664-B2 Small molecule inhibitors of SRC tyrosine kinase SRC, CTTN, LCK SRC 1/4885MAP3K7 42/4885FGFR1 235/4885
US-20220267294-A1 SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE SRC, CTTN, LCK SRC 1/4885MAP3K7 42/4885FGFR1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.